For example, a phase II clinical trial was conducted to investigate the effectiveness of figitumumab (CP-751,871), an IGF-1R monoclonal antibody, in combination with chemotherapy (carboplatin and paclitaxel) for treating advanced NSCLC in patients. Here, IGF1R is linked to non-small cell lung carcinoma.